PEAR Therapeutics scores $50 mln Series B
Boston and San Francisco-based PEAR Therapeutics, a provider of prescription digital therapeutics, has secured $50 million in Series B financing. Temasek led the round with participation from other investors that included 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, EDBI and the Bridge Builder’s Collaborative.
2 January 2018•1 min read
